GlassScriptPhysician profile
Scott J Lamb
NPI 1831192277
$1,899.41
in general payments reported to CMS, 2019-2025
24 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.66 · 2020: $119 · 2021: $121 · 2022: $382 · 2023: $384 · 2024: $506 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $389.15 | 2023-2025 | Belbuca, Xtampza, Nucynta |
| Abbvie INC. | $337.21 | 2022-2025 | |
| Abbott Laboratories | $225.67 | 2019-2024 | Eterna |
| Boston Scientific Corporation | $151.14 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, Na |
| Relievant Medsystems, INC. | $150.52 | 2022 | |
| Curonix LLC | $112.01 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nevro Corp. | $63.73 | 2022 | |
| Scilex Pharmaceuticals INC. | $60.58 | 2021-2023 | Ztlido |
| Amgen INC. | $45.97 | 2020 | |
| Bioventus LLC | $45.90 | 2023 | Durolane |
| Amneal Pharmaceuticals LLC | $33.65 | 2023 | Lyvispah |
| Kowa Pharmaceuticals America, INC. | $32.36 | 2023 | Seglentis |
| Lilly USA, LLC | $27.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.18 | 2022 | |
| Nalu Medical, INC. | $24.68 | 2024 | Nalu Neurostimulation System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $24.49 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $24.14 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $22.43 | 2022 | |
| Innovation Technologies INC | $19.37 | 2022 | |
| Lundbeck LLC | $19.22 | 2022 | |
| Painteq LLC | $18.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.01 | 2021 | |
| Forte Bio-Pharma LLC | $14.74 | 2024 | Prolate, Nalocet |
| Pfizer INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.